DUE DILIGENCE

Judging the pharmaceutical potential of a compound which is available as an in-licensing opportunity is a situation small companies frequently encounter.

Using it’s network of highly experienced pharmaceutical development and marketing experts, BaselBio1 can perform an in-depth analysis of the data available for such a compound and provide you with a risk-benefit analysis of the in-licensing candidate and, when positive, with a projection of remaining development costs and time to market.